CD4 and myeloid sarcoma: Notably, most fingolimod-treated MS patients exhibit a robust response to VZV, and only those who lack this response experience viral reactivation (109) The lack of response may be related to the finding that fingolimod can also impact CD4+ effector T-cell function through the upregulation of T-cell factor 1 (94).